LOGO.jpg
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – AQST
March 06, 2021 11:19 ET | The Rosen Law Firm PA
NEW YORK, March 06, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
NeptuneDash_Icon_DAC-1500x500-white-bg.png
Neptune Digital Assets Announces Bitcoin Mining Operations and Partnership With Link Global
March 04, 2021 07:00 ET | Neptune Digital Assets Corp.
VANCOUVER, British Columbia, March 04, 2021 (GLOBE NEWSWIRE) -- Neptune Digital Assets Corp. (TSX-V:NDA) (OTC:NPPTF) (FSE:1NW) (“Neptune” or the "Company") is excited to announce that it will begin...
LOGO.jpg
ROSEN, LEADING INVESTOR COUNSEL, Encourages Tricida Inc. Investors to Secure Counsel Before Important March 8 Deadline – TCDA
February 18, 2021 20:15 ET | The Rosen Law Firm PA
NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Tricida, Inc. (NASDAQ: TCDA) between September 4, 2019 and...
LOGO.jpg
ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Tricida Inc. Investors with Losses Over $100K to Secure Counsel Before Important March 8 Deadline – TCDA
February 15, 2021 12:18 ET | The Rosen Law Firm PA
NEW YORK, Feb. 15, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Tricida, Inc. (NASDAQ: TCDA) between September 4, 2019 and...
LOGO.jpg
ROSEN, GLOBALLY RESPECTED INVESTOR COUNSEL, Reminds Fortress Biotech, Inc. Investors of Important Deadline in Securities Class Action - FBIO
January 08, 2021 19:15 ET | The Rosen Law Firm PA
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fortress Biotech, Inc. (NASDAQ: FBIO) between December 11, 2019...
LOGO.jpg
ROSEN, A LEADING AND LONGSTANDING FIRM, Reminds Minerva Neurosciences, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – NERV
January 08, 2021 17:08 ET | The Rosen Law Firm PA
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Minerva Neurosciences, Inc. (NASDAQ: NERV) between May 15, 2017...
LOGO.jpg
ICPT FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact Firm – ICPT
January 01, 2021 19:15 ET | The Rosen Law Firm PA
NEW YORK, Jan. 01, 2021 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) between...
axsomelogo-468x57.jpg
Axsome Therapeutics Announces Positive Efficacy and Safety Results from Phase 3 COMET Long-Term Trial and COMET-AU Trial of AXS-05 in Major Depressive Disorder
December 01, 2020 06:00 ET | Axsome Therapeutics, Inc.
Rapid and substantial improvement in depressive symptoms achieved by 40% of patients at 2 weeks, 73% at 6 weeks (MADRS response), and sustained over 12 months Rapid and substantial improvement in...
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Reminds Zosano Pharma Corporation Investors of Important Deadline in Securities Class Action – ZSAN
November 18, 2020 13:08 ET | The Rosen Law Firm PA
NEW YORK, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Zosano Pharma Corporation (NASDAQ: ZSAN) between February 13,...
axsomelogo-468x57.jpg
Axsome Therapeutics Completes Successful FDA Pre-NDA Meeting for AXS-07 for the Acute Treatment of Migraine
August 20, 2020 07:00 ET | Axsome Therapeutics, Inc.
 NDA submission on track for 4Q 2020 NEW YORK, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management...